profit from every $100 of sales.
$0$100
Spyre Therapeutics
$106.82+2.24% today
+357.5% in 1 year
1-year low $22.631-year high $109.00
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2018 to 2023.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Spyre Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $2.33 million in 2022 to $0 in 2025, with -$155 million of profit last year.
SalesProfit
Spyre Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Spyre Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Spyre Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 0 | 19 | 2 | 1 | 0 | 0 | |
| – | – | – | – | – | – | |
| -81 | -66 | -85 | -129 | -209 | -220 | |
| -80 | -64 | -83 | -128 | -209 | -220 | |
| -81 | -66 | -84 | -339 | -208 | -155 | |
| – | – | -24.75 | -13.76 | -3.18 | -1.98 | |
| – | – | – | – | – | – | |
| – | -350.3% | -3,640.2% | -14,510.6% | – | – | |
| – | -351.1% | -3,598.8% | -38,238.1% | – | – |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 162 | 110 | 71 | 342 | 608 | 778 |
| Cash | 90 | 15 | 35 | 189 | 89 | 86 |
| Total debt | – | – | 5 | 0 | – | – |
| Total liabilities | 22 | 26 | 21 | 158 | 91 | 63 |
| 140 | 84 | 50 | 184 | 518 | 715 | |
| 2 | 3 | 3 | 7 | 47 | 64 | |
| -46.0% | -61.8% | -121.9% | -55.2% | -31.8% | -24.3% | |
| -57.9% | -78.4% | -166.6% | -184.1% | -40.2% | -21.7% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -76 | -54 | -80 | -100 | -157 | -169 | |
| 4 | 1 | 0 | 0 | 0 | – | |
| -80 | -54 | -80 | -100 | -157 | -169 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 6 | 8 | 7 | 26 | 45 | 38 |
Valuation
- –
- –
- –
- 14.5×
- 11,449.9×
- –
- –
- -1.0%
- -3.3%
- 0.0%
Profitability
- 0.0%
- -14,510.6%
- -38,238.1%
- -222.4%
- -24.9%
- -59.8%
- -31.2%
- -23.5%
- -34.1%
- 210.4%
Growth
- −25.6%
- –
- −7.5%
- –
- +166.8%
Financial health
- -1.5×
- 0.00
- 0.0%
- –
- 13.25
- 8.97
- 0.12
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 958
Bottom 4%of 890
Bottom 32%of 987
What analysts expect
- Average price target
- $81.90
- Range
- $49.00 – $106.00
- 9 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.74 | -0.66 | −12.1% |
| Feb 19, 2026 | -0.70 | -0.66 | −6.1% |
| Nov 4, 2025 | -0.15 | -0.68 | +77.9% |
| Aug 5, 2025 | -0.49 | -0.73 | +32.9% |
| May 8, 2025 | -0.74 | -0.76 | +2.6% |
| Feb 27, 2025 | -0.81 | -0.89 | +9.0% |
| Nov 7, 2024 | -1.36 | -0.80 | −70.0% |
| Aug 7, 2024 | -0.86 | -0.90 | +4.4% |
News
Biggest stock movers Wednesday: SYRE, INTU, SAP and moreSeeking Alpha · Aug 26, 2026Spyre drops on disappointing phase 2 data for rheumatoid arthritis assetSeeking Alpha · Aug 25, 2026The newest story we have is from Aug 26, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
40No pass
Philip Fisher
38No pass
Peter Lynch
40No pass
Joel Greenblatt
0No pass
Charlie Munger
40No pass
Terry Smith
34No pass
Questions about Spyre Therapeutics
Is Spyre Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Spyre Therapeutics AI analysis
What does Spyre Therapeutics do?
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. It is in Biotechnology, based in Waltham, MA, United States, with 112 employees.
Does Spyre Therapeutics pay a dividend?
No. Spyre Therapeutics does not pay a dividend at the moment.
Is Spyre Therapeutics stock halal?
Yes. Spyre Therapeutics passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has Spyre Therapeutics stock done over the past year?
Up 357.5% over the past twelve months, to $106.82. It traded between $22.63 and $109.00 and is 2.0% below its high.
Who are Spyre Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Spyre Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.